{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:19:29Z","timestamp":1787552369832,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:italic>De novo<\/jats:italic>\n                    CD20-negative Epstein\u2013Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS), is a rare subtype of DLBCL. CD20 loss complicates both diagnosis and treatment by limiting anti-CD20 antibody use and broadening differential diagnosis. We report a case where comprehensive immunophenotypic and molecular analyses enabled accurate diagnosis. A biomarker-driven strategy combining CD30-targeted therapy and PD-1 blockade achieved a complete metabolic response. This case underscores the importance of biology-based individualized treatment in EBV-associated lymphomas and the need for prospective studies of CD20-independent strategies in high-risk patients.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1878880","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:30:41Z","timestamp":1787549441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein\u2013Barr virus-positive diffuse large B-cell lymphoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingjing","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Head & Neck Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Head & Neck Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiurong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Head & Neck Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghu","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Head & Neck Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoguang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Head & Neck Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27430","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management","volume":"99","author":"Malpica","year":"2024","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1066896917735170","article-title":"De novo unclassifiable CD20-negative diffuse large B-cell lymphoma: A diagnostic and therapeutic challenge","volume":"26","author":"Abdullgaffar","year":"2018","journal-title":"Int J Surg Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1066896918784669","article-title":"Epstein-Barr virus\u2013positive CD20- and CD45-negative diffuse large B-cell lymphoma: A diagnostic challenge","volume":"27","author":"Starr","year":"2018","journal-title":"Int J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1387912","article-title":"Survival of patients with CD20-negative variants of large B-cell lymphoma: An analysis of the National Cancer Data Base","volume":"59","author":"Qunaj","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020400","article-title":"Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies","volume":"142","author":"Ang","year":"2023","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12946","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142","volume":"70","author":"Sakakibara","year":"2020","journal-title":"Pathol Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004515","article-title":"Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified","volume":"5","author":"Bourbon","year":"2021","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000126781.87158.e3","article-title":"Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities","volume":"28","author":"Colomo","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032277","article-title":"Chronic active Epstein-Barr virus disease: Molecular pathogenesis, evolving concepts, and emerging therapies","volume":"147","author":"Kimura","year":"2026","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13000-017-0606-7","article-title":"An unusual case of Epstein-Barr virus-positive large B-cell lymphoma lacking various B-cell markers","volume":"12","author":"Nakatsuka","year":"2017","journal-title":"Diagn Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177469","article-title":"Diffuse large B-cell lymphoma: Reduced CD20 expression is associated with an inferior survival","volume":"113","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-15-0781","article-title":"Anti-CD20 therapy acts via Fc\u03b3RIIIA to diminish responsiveness of human natural killer cells","volume":"75","author":"Capuano","year":"2015","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-736066","article-title":"HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies","volume":"130","author":"Bobrowicz","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: An \"enigma\" of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16342","article-title":"Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-virus positive diffuse large B cell lymphoma","volume":"189","author":"Witte","year":"2020","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2021","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000889","article-title":"EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2","volume":"134","author":"Cristino","year":"2019","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s44313-024-00042-6","article-title":"PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: A retrospective analysis","volume":"59","author":"Li","year":"2024","journal-title":"Blood Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000655","article-title":"Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms","volume":"3","author":"Hong","year":"2019","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ajh.25049","article-title":"Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review","volume":"93","author":"Marchetti","year":"2018","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.708931","article-title":"Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained","volume":"54","author":"Witzig","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1878880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:30:45Z","timestamp":1787549445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1878880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1878880"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1878880","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1878880"}}